Company intelligence / Profile preview

Biofidelity

Cambridge, Cambridgeshire, United Kingdombiofidelity.com ↗

Ownership: Private
Development stage: Commercial

Overview

Biofidelity has launched ASPYRE-Lung in the US, which identifies guideline-recommended biomarkers for targeted therapies in lung cancer patients. The test provides results faster and at lower cost than traditional sequencing methods.

Therapeutic areas: Oncology
Modalities: Genomic testingMolecular diagnostics
Industry: Molecular Diagnostics

Drug pipeline

2 assets

ASPYRE-Lung

Commercial

Indications: Non-small cell lung cancer

1 more asset in the full pipeline.

Request access →

Partnerships

Agilent Technologies

Beyond the preview

Go deeper on Biofidelity.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biofidelity.

Explore the full profile